Black Rock Inc. Paratek Pharmaceuticals, Inc. Transaction History

Black Rock Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$1.52 - $2.8 $261,617 - $481,927	-172,117 Reduced 16.13%	894,894 $1.98 Million
Q1 2023 May 12, 2023	SELL	$1.37 - $2.54 $153,138 - $283,921	-111,780 Reduced 9.48%	1,067,011 $2.71 Million
Q4 2022 Feb 13, 2023	SELL	$1.67 - $2.51 $41,173 - $61,884	-24,655 Reduced 2.05%	1,178,791 $2.2 Million
Q3 2022 Nov 14, 2022	BUY	$1.96 - $2.93 $655,075 - $979,270	334,222 Added 38.45%	1,203,446 $3.09 Million
Q2 2022 Aug 12, 2022	SELL	$1.73 - $3.09 $3.58 Million - $6.4 Million	-2,071,289 Reduced 70.44%	869,224 $1.68 Million
Q1 2022 May 12, 2022	SELL	$2.94 - $4.77 $109,270 - $177,286	-37,167 Reduced 1.25%	2,940,513 $8.73 Million
Q4 2021 Feb 10, 2022	BUY	$4.07 - $5.3 $246,397 - $320,862	60,540 Added 2.08%	2,977,680 $13.4 Million
Q3 2021 Nov 09, 2021	BUY	$4.7 - $7.24 $93,154 - $143,496	19,820 Added 0.68%	2,917,140 $14.2 Million
Q2 2021 Aug 11, 2021	BUY	$6.81 - $10.93 $19.7 Million - $31.7 Million	2,897,320 New	2,897,320 $19.8 Million

1.54M

Ticker PRTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,862,500
Description
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectru...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.